Rate Video

EBMT 2020 | HDAC inhibitors: panobinostat for R/R myeloma

Noopur Raje • 25 Aug 2020

Multiple Myeloma Bortezomib Carfilzomib Citarinostat Ricolinostat

Noopur Raje, MD, Massachusetts General Hospital, Boston, MA, discusses the use of histone deacetylase (HDAC) inhibitors, specifically panobinostat, for the treatment of relapsed/refractory (R/R) multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

CAR-T: hurdles and ladders

Adam Cohen et al. • 13 Sep 2019

Results of Phase Ib/II study of ricolinostat in multiple myeloma

Noopur Raje • 9 Jun 2016

Trial updates in R/R MM from ASCO: ARROW, MMY1001 & OPTIMISMM

Noopur Raje • 1 Jun 2018

Immuno-oncology agents for MM: checkpoint inhibitors and NK-cells

Noopur Raje • 1 Jun 2018

Related Videos

Maintenance therapy in young patients with myeloma

Graham Jackson • 5 Mar 2021

BVD in heavily pretreated multiple myeloma

Claudio Cerchione • 3 Mar 2021

#woMMen: network of women in multiple myeloma

Nina Shah • 3 Mar 2021

Frailty subgroup analysis of the MAIA trial

Gordon Cook • 2 Mar 2021